Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Haussaire, Delphine; Fournier, Pierre-Edouard; Djiguiba, Karamoko; Moal, Valerie; Legris, Tristan; Purgus, Rajsingh; Bismuth, Jeremy; Elharrar, Xavier; Reynaud-Gaubert, Martine; Vacher-Coponat, Henri (2017)
Publisher: Elsevier BV
Journal: International Journal of Infectious Diseases
Languages: English
Types: Article
Subjects: RC109-216, Cystic fibrosis, Transplantation, Infectious Diseases, Infectious and parasitic diseases, Nocardiosis, Cancer, [ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Opportunistic infection, Microbiology (medical)
International audience; Background: Nocardiosis is a rare disease with polymorphic presentations. The epidemiology and clinical presentation could change with the increasing number of immunocompromised patients. Methods: The medical records and microbiological data of patients affected by nocardiosis and treated at the university hospitals of Marseille between 2004 and 2014 were analyzed retrospectively. Results: The cases of 34 patients infected by Nocardia spp during this period were analyzed. The main underlying conditions were transplantation (n = 15), malignancy (n = 9), cystic fibrosis (n = 4), and immune disease (n = 3); no immunodeficiency condition was observed for three patients. No case of AIDS was observed. At diagnosis, 61.8% had received steroids for over 3 months. Four clinical presentations were identified, depending on the underlying condition: the disseminated form (50.0%) and the visceral isolated form (26.5%) in severely immunocompromised patients, the bronchial form (14.7%) in patients with chronic lung disease, and the cutaneous isolated form (8.8%) in immunocompetent patients. Nocardia farcinica was the main species identified (26.5%). Trimethoprim-sulfamethoxazole was prescribed in 68.0% of patients, and 38.0% underwent surgery. Mortality was 11.7%, and the patients who died had disseminated or visceral nocardiosis. Conclusions: The clinical presentation and outcome of nocardiosis depend on the patient's initial immune status and underlying pulmonary condition. Severe forms were all iatrogenic, occurring after treatments altering the immune system. (C) 2017 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Provost F, Laurent F, Blanc MV, Boiron P. Transmission of nocardiosis and molecular typing of Nocardia species: a short review. Eur J Epidemiol 1997;13:235-8.
    • 2. Clark NM, Reid GE. AST Infectious Diseases Community of Practice. Nocardia infections in solid organ transplantation. Am J Transplant 2013;13(Suppl 4):83- 92. doi:http://dx.doi.org/10.1111/ajt.12102.
    • 3. Javaly K, Horowitz HW, Wormser GP. Nocardiosis in patients with human immunodeficiency virus infection: Report of 2 cases and review of the literature. Medicine (Baltimore) 1992;71:128-38.
    • 4. Beaman BL, Beaman L. Nocardia species: host-parasite relationships. Clin Microbiol Rev 1994;7:213-64.
    • 5. Hui CH, Au VWK, Rowland K, Slavotinek JP, Gordon DL. Pulmonary nocardiosis re-visited: experience of 35 patients at diagnosis. Respir Med 2003;97:709-17.
    • 6. Farina C, Boiron P, Ferrari I, Provost F, Goglio A. Report of human nocardiosis in Italy between 1993 and 1997. Eur J Epidemiol 2001;17:1019-22.
    • 7. Brown-Elliott BA, Brown JM, Conville PS, Wallace RJ. Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy. Clin Microbiol Rev 2006;19:259-82. doi:http://dx.doi.org/10.1128/CMR.19.2.259- 282.2006.
    • 8. Bell Melissa, Mc Neil Michael, Brown June M. Nocardia species (nocardiosis)- infectious disease and antimicrobial agents. Epidemiology and Surveillance Division National Immunization Program. Atlanta: Centers for Disease Control and Prevention; 2017http://www.antimicrobe.org/b117.asp.
    • 9. Husain S, McCurry K, Dauber J, Singh N, Kusne S. Nocardia infection in lung transplant recipients. J Heart Lung Transplant 2002;21:354-9.
    • 10. Mootsikapun P, Intarapoka B, Liawnoraset W. Nocardiosis in Srinagarind Hospital, Thailand: review of 70 cases from 1996-2001. Int J Infect Dis 2005;9:154-8. doi:http://dx.doi.org/10.1016/j.ijid.2004.06.011.
    • 11. Martínez Tomás R, Menéndez Villanueva R, Reyes Calzada S, Santos Durantez M, Vallés Tarazona JM, Modesto Alapont M, et al. Pulmonary nocardiosis: risk factors and outcomes. Respirology 2007;12:394-400. doi:http://dx.doi.org/ 10.1111/j.1440-1843.2007.01078.x.
    • 12. Minero MV, Marín M, Cercenado E, Rabadán PM, Bouza E, Muñoz P. Nocardiosis at the turn of the century. Medicine (Baltimore) 2009;88:250-61. doi:http://dx. doi.org/10.1097/MD.0b013e3181afa1c8.
    • 13. Rosman Y, Grossman E, Keller N, Thaler M, Eviatar T, Hoffman C, et al. Nocardiosis: a 15-year experience in a tertiary medical center in Israel. Eur J Intern Med 2013;24:552-7. doi:http://dx.doi.org/10.1016/j.ejim.2013.05.004.
    • 14. Al-Jahdali H, Baharoon S, Alothman S, Memish Z, Waness A. Nocardiosis in a tertiary care hospital in Saudi Arabia. J Glob Infect Dis 2011;3:128-32. doi: http://dx.doi.org/10.4103/0974-777X.81688.
    • 15. Garcia-Bellmunt L, Sibila O, Solanes I, Sanchez-Reus F, Plaza V. Pulmonary nocardiosis in patients with COPD: characteristics and prognostic factors. Arch Bronconeumol 2012;48:280-5. doi:http://dx.doi.org/10.1016/j. arbres.2012.04.009.
    • 16. Kurahara Y, Tachibana K, Tsuyuguchi K, Akira M, Suzuki K, Hayashi S. Pulmonary nocardiosis: a clinical analysis of 59 cases. Respir Investig 2014;52:160-6. doi:http://dx.doi.org/10.1016/j.resinv.2013.09.004.
    • 17. Rodríguez-Nava V, Couble A, Devulder G, Flandrois JP, Boiron P, Laurent F. Use of PCR-restriction enzyme pattern analysis and sequencing database for hsp65 gene-based identification of Nocardia species. J Clin Microbiol 2006;44:536-46. doi:http://dx.doi.org/10.1128/JCM.44.2.536-546.2006.
    • 18. Chen J, Zhou H, Xu P, Zhang P, Ma S, Zhou J. Clinical and radiographic characteristics of pulmonary nocardiosis: clues to earlier diagnosis. PLoS One 2014;9:e90724. doi:http://dx.doi.org/10.1371/journal.pone.0090724.
    • 19. Yang M, Xu M, Wei W, Gao H, Zhang X, Zhao H, et al. Clinical findings of 40 patients with nocardiosis: a retrospective analysis in a tertiary hospital. Exp Ther Med 2014;8:25-30. doi:http://dx.doi.org/10.3892/etm.2014.1715.
    • 20. Hardak E, Yigla M, Berger G, Sprecher H, Oren I. Clinical spectrum and outcome of Nocardia infection: experience of 15-year period from a single tertiary medical center. Am J Med Sci 2012;343:286-90. doi:http://dx.doi.org/10.1097/ MAJ.0b013e31822cb5dc.
    • 21. Cattaneo C, Antoniazzi F, Caira M, Castagnola C, Delia M, Tumbarello M, et al. Nocardia spp infections among hematological patients: results of a retrospective multicenter study. Int J Infect Dis 2013;17 e:610-4. doi:http://dx.doi.org/ 10.1016/j.ijid.2013.01.013.
    • 22. Peleg AY, Husain S, Qureshi ZA, Silveira FP, Sarumi M, Shutt KA, et al. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis 2007;44:1307-14. doi:http://dx.doi.org/10.1086/514340.
    • 23. Liu WL, Lai CC, Ko WC, Chen YH, Tang HJ, Huang YL, et al. Clinical and microbiological characteristics of infections caused by various Nocardia species in Taiwan: a multicenter study from 1998 to 2010. Eur J Clin Microbiol Infect Dis 2011;30:1341-7. doi:http://dx.doi.org/10.1007/s10096-011-1227-9.
    • 24. Zheng YC, Wang TL, Hsu JC, Hsu YH, Hsu WH, Wang CL, et al. Clinical pathway in the treatment of nocardial brain abscesses following systemic infections. Case Rep Neurol Med 2014;2014:584934. doi:http://dx.doi.org/10.1155/2014/ 584934.
    • 25. Marnet D, Brasme L, Peruzzi P, Bazin A, Diallo R, Servettaz A, et al. [Nocardia brain abscess: features, therapeutic strategies and outcome]. Rev Neurol (Paris) 2009;165:52-62. doi:http://dx.doi.org/10.1016/j.neurol.2008.06.012.
    • 26. Mamelak AN, Obana WG, Flaherty JF, Rosenblum ML. Nocardial brain abscess: treatment strategies and factors influencing outcome. Neurosurgery 1994;35:622-31.
    • 27. Wang HK, Sheng WH, Hung CC, Chen YC, Lee MH, Lin WS, et al. Clinical characteristics, microbiology, and outcomes for patients with lung and disseminated nocardiosis in a tertiary hospital. J Formos Med Assoc 2015;114:742-9. doi:http://dx.doi.org/10.1016/j.jfma.2013.07.017.
    • 28. Ferrer A, Llorenç V, Codina G, de Gracia-Roldán J. [Nocardiosis and bronchiectasis: An uncommon association?]. Enferm Infecc Microbiol Clin 2005;23:62-6.
    • 29. Thorn ST, Brown MA, Yanes JJ, Sherrill DL, Pugmire J, Anderson KA, et al. Pulmonary nocardiosis in cystic fibrosis. J Cyst Fibros 2009;8:316-20. doi: http://dx.doi.org/10.1016/j.jcf.2009.07.005.
    • 30. Rodriguez-Nava V, Durupt S, Chyderiotis S, Freydière AM, Karsenty J, de Montclos M, et al. A French multicentric study and review of pulmonary Nocardia spp. in cystic fibrosis patients. Med Microbiol Immunol (Berl) 2015;204:493-504. doi:http://dx.doi.org/10.1007/s00430-014-0360-3.
    • 31. Brown-Elliott BA, Biehle J, Conville PS, Cohen S, Saubolle M, Sussland D, et al. Sulfonamide resistance in isolates of Nocardia spp. from a US multicenter survey. J Clin Microbiol 2012;50:670-2. doi:http://dx.doi.org/10.1128/ JCM.06243-11.
    • 32. Schlaberg R, Fisher MA, Hanson KE. Susceptibility profiles of Nocardia isolates based on current taxonomy. Antimicrob Agents Chemother 2014;58:795-800. doi:http://dx.doi.org/10.1128/AA.C.01531-13.
    • 33. Gomez-Flores A, Welsh O, Said-Fernández S, Lozano-Garza G, TavarezAlejandro RE, Vera-Cabrera L. In vitro and in vivo activities of antimicrobials against Nocardia brasiliensis. Antimicrob Agents Chemother 2004;48:832-7.
    • 34. Moylett EH, Pacheco SE, Brown-Elliott BA, Perry TR, Buescher ES, Birmingham MC, et al. Clinical experience with linezolid for the treatment of Nocardia infection. Clin Infect Dis 2003;36:313-8. doi:http://dx.doi.org/10.1086/345907.
    • 35. Peraira JR, Segovia J, Fuentes R, Jiménez-Mazuecos J, Arroyo R, Fuertes B, et al. Pulmonary nocardiosis in heart transplant recipients: treatment and outcome. Transplant Proc 2003;35:2006-8.
    • 36. Wilson JP, Turner HR, Kirchner KA, Chapman SW. Nocardial infections in renal transplant recipients. Medicine (Baltimore) 1989;68:38-57.
  • No related research data.
  • No similar publications.